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ABSTRACT 
 
 
 Current anticoagulant agent such as warfarin and heparin have demonstrated life- 
threatening side effect and its efficacy also been doubted. So, exploration of herbal plant 
been done and one of them is Mikania cordata. Mikania cordata (Bum. F.) B.L 
Robinson or commonly called selaput tunggul, in Malaysia, belongs to family of 
Asteraceae and it was claimed to prolonged PT (prothrombin time), APTT (activated 
partial thromboplastin time) and TT (thrombin time) in early study. Thus, aim in this 
study were to identify the active compound through GCMS analysis and to determine 
level of factors VII, IX, X, II and FGN in plasma treated in vitro with different 
concentrations of M.cordata aqueous leaves extract. As a result, in 25.0 mg/ml of M. 
cordata extract, significant percentage of factor reduced can be observed which were in 
FII with 90.17%, followed by FGN (89.80%), FX (80.91%), FIX (69.15%) and finally 
FVII (62.67%) compared to control with p < 0.001.This finding was supported by the 
identification of malic acid which was believed to possess anticoagulant activity. Malic 
acid also reacts in concentration- dependent manner when 25.0 mg/ml of M. cordata 
extract treated on plasma showed high reduction of factors compared to 12. 5 mg/ml. In 
conclusion, it was confirmed that malic acid possess anticoagulant activity in 
concentration dependent manner, by reducing level of factors VII, IX, X, FII and FGN 
in plasma. 
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ABSTRAK 
 
 
Egen anti pembekuan darah yang sedia ada seperti warfarin dan heparin 
dilaporkan mempunyai kesan sampingan yang membahayakan, nyawa, malah, 
keberkesanannya juga turut diragukan. Oleh itu, kajian mula dilakukan terhadap 
tumbuhan herba dan antaranya ialah Mikania cordata. Mikania cordata (Bum. F.) B.L 
Robinson atau dikenali sebagai selaput tunggul di Malaysia, tergolong dalam keluarga 
Asteraceae dan dipercayai mampu melanjutkan masa pembekuan darah dalam ujian PT 
(masa prothrombin), APTT (pengaktifan separa masa tromboplastin) dan TT (masa 
thrombin) dalam kajian terdahulu. Oleh itu, kajian ini dijalankan untuk mengenalpasti 
komponen aktif menggunakan analisis GCMS dan untuk mengkaji tahap faktor VII, IX, 
X, II dan FGN dalam plasma yang dicampur ekstrak daun M.cordata dengan kepekatan 
yang berbeza. Hasil kajian menunjukkan, dalam 25.0 mg/ml ekstrak, peratusan faktor 
berkurang sangat ketara dengan p < 0.001 iaitu dalam FII sebanyak 90.17%, diikuti 
FGN (89.80%), FX (80.91%), FIX (69.15%) dan FVII (62.67%) setelah dibandingkan 
dengan kontrol. Hasil kajian ini diperkukuhkan lagi dengan penemuan asid malik yang 
dipercayai memiliki aktiviti anti pembekuan darah. Tindakan asid malik sebagai anti 
pembekuan darah bergantung kepada kepekatan ekstrak yang digunakan dan dibuktikan, 
dalam kepekatan 25.0 mg/ml, peratus penurunan faktor adalah tertinggi berbanding 12.5 
mg/ml. Kesimpulannya, asid malik memiliki sifat anti pembekuan darah dengan 
menyakibatkan penurunkan tahap faktor VII, IX, X, FII dan FGN dalam plasma. 
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CHAPTER 1 
 
 
INTRODUCTION 
 
 
1.1 Research Background 
 
Blood coagulation cascade involved a series of sequential steps which include 
intrinsic, extrinsic and common pathways. They are propagated by the formation of 
complex enzymes which  is serine protease ( factor II,VII, IX, X, XI and XII) and non-
enzymatic cofactor protein which assembled on membrane surface in calcium-
dependent manner (Butenas & Mann, 2001). Hence, maintaining of component level in 
vascular system is essential because this sequential cascade may decide the formation of 
thrombin thus directs the aggregation of blood via polymerization of fibrin (Hoffbrand 
et al., 2011).  
 
Overproduction of clot then leads to the formation of thrombus. There are two 
types of thrombosis which are venous thrombosis and arterial thrombosis. Venous 
thrombosis encompasses deep vein thrombosis (DVT) and pulmonary embolism (PE). 
Meanwhile major manifestations of arterial thrombosis are cardiac ischaemic, stroke 
and possibly peripheral vascular disease (thrombosis in leg arteries) (Previtali et al., 
2011). In order to treat thrombosis diseases, antiplatelet and anticoagulant have been 
introduced. Antiplatelet can inhibit the production of thromboxane, thus avoid 
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formation of clot and anticoagulant act by targeting clotting factors of blood coagulation 
  s           r et al., 2004).   
 
Currently, synthetic drugs such as warfarin and heparin are widely been used as 
anticoagulant agent. However, there are several disadvantages such as the life- 
threatening side effect and undoubted efficacy of the drug (Jain et al., 2014; Manicam et 
al., 2010). Specifically, for vitamin K antagonist (warfarin), the well- known side effect, 
narrow therapeutic index, unevenness of dose response and the dietary interaction still 
remains as the limitation (Garcia et al., 2009). Therefore, development of novel 
anticoagulant agent been progressed to overcome the limitation, nevertheless the cost is 
too expensive and somewhat affect the productivity of study.  
 
As a result, exploration of herbal plant been done. In fact, according to Hammer 
et al. (1999), plant contains abundant resources of chemical compound which can be 
used for treatment in modern medicines, food supplement and nutraceuticals. To date, 
billions of dollars have been earned through market trafficking due to augment of herbal 
medicine every year. However, the true machinery of action of herbal plants on diseases 
is not truly known. In a period of hundred years, numerous medicinal plants have been 
utilized by human being across the world for the management of diverse sickness and 
diseases without knowing the true mechanism (Marcus & Grollman, 2002).    
 
Therefore, the discovery of blood coagulation factor level after treated with 
Mikania cordata is warranted since it have been claimed to prolonged  PT (prothrombin 
time), APTT (activated partial thromboplastin time) and TT (thrombin time) in human 
plasma.  This preliminary result indicated that M.cordata would act as anticoagulant 
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agent such as heparin and warfarin (Shaffee et al., 2015). Hence, in vitro factor assay 
was adopted to elucidate the specific mechanism of action of M.cordata aqueous extract 
on blood coagulation system. 
 
1.2 Rationale of Study 
 
M.cordata aqueous extract was found to prolonged PT, APTT and TT in clot-
based assays treated to human blood (Shaffee et al., 2015). This preliminary finding 
indicated that, M.cordata aqueous extract has a big potential to act as anticoagulant 
agent which might treat thrombosis diseases. As a consequence, study was conducted to 
elucidate the specific mechanism of blood coagulation system after treated with 
M.cordata aqueous extract which focus on the factor level that are important as a key 
player in blood coagulation system.  
 
1.3 Objectives 
 
1.3.1 General Objective 
 
To study blood coagulation factors level in plasma treated in vitro with M.cordata 
aqueous leaves extract. 
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1.3.2 Specific objective  
 
The specific objectives in this study are as follows: 
a) To identify active compound in M.cordata using GCMS analysis. 
b)  To determine the level of factors VII, IX, X, II, fibrinogen in plasma treated in 
vitro with different concentration of M.cordata aqueous leaves extract. 
 
1.4 Hypothesis 
 
HO: There are no changes of coagulation factors level in plasma treated in vitro with 
M.cordata aqueous leaves extract. 
 
HA: There are changes of coagulation factors level in plasma treated in vitro with 
M.cordata aqueous leaves extract. 
 
1.5 Significance of Study  
 
Result of this study may contribute to the body of knowledge and hence improve 
understanding about the mechanism of action of M.cordata as anticoagulant agent. 
Further study need to be done completely to elucidate the capability of M.cordata 
before it can be declares as novel anticoagulant agent. Therefore, by understanding the 
mechanisms of M.cordata action on diseases, specific indication of the usage can be 
made. 
 
 
 
5 
 
CHAPTER 2 
 
 
LITERATURE REVIEW 
 
 
2.1 Overview of haemostasis 
 
Haemostasis (Greek word; haem refer to blood and stasis is halt) is defined as 
interruption of blood flow or blood restrain either by natural means (clot formation or 
vessel spasm) or artificial means (compression or ligation) (Miller-Keane et al., 2005). 
Haemostatic system is a possessive process which represents a mild equity between 
procoagulant and anticoagulant which stop the bleeding from spots of blood vessel 
destruction and thus disintegrate the clot formation (Hoffbrand et al., 2011).  
 
Following vascular destruction, haemostasis response started. In haemostasis, 
there are three main mechanisms involved, which are vasoconstriction, platelet 
aggregation and blood coagulation cascade (Figure 2.1). Synergy between all 
mechanism lead to the formation of secure haemostasis plug.  Nevertheless, 
development of extensive clot is very dangerous. Therefore, fibrinolysis mechanism is 
very important in vascular system. 
 
Blood coagulation cascade is part of the vital mechanism which involved 
extrinsic, intrinsic and common pathway which connects to form fibrin polymer. Plasma 
consists of several factors which work together with the aid of many other cofactor, 
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inhibitor and receptor to produce fibrin polymer. Table 2.1 demonstrates the key protein 
involved in haemostasis network. 
 
 
 
Figure 2.1 Haemostasis networks which involved three main mechanism; 
vasoconstriction, platelet aggregation and blood coagulation cascade (adapted from 
Hoffbrand et al., 2011) 
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2.2 Blood coagulation cascade 
 
In vivo, initiation of blood coagulation begins when tissue factors (TF) express 
on cells is exposed to plasma contain FVII.  According to Hoffbrand et al. (2011), only 
one to two percent of total factor VII present in activated formed while the rest are in 
inactive state whereby only become stimulated after bound to TF. TF or contact system 
is indirectly contributed to physiological of haemostasis (Peterson et al., 1995). 
 
High binding of FVIIa on TF at vascular surface leads to the formation of TF- 
FVIIa complex. These, in turn, enable the generation of FIXa and FXa. The generation 
is initiates by serine protease activity (Figure 2.2). The generation of activated formed 
of factors subsequently allow the formation of thrombin and yet fibrin monomer (Furie 
et al., 2008). However, in the first stage of activation, only small amount of thrombin 
form from prothrombin. At this stage, it is expeditiously inactivated by tissue factor 
pathway inhibitor (TFPI). Therefore, second stage of activation is requires to outburst 
the production of thrombin. In the second stage of activation or so-called amplification, 
coenzymes FV, FVIII and FXI are back-activate by limiting the proteolysis after 
insufficient thrombin formed (Gugliemone et al., 2001; Chu, 2011). 
 
 
 
 
 
 
 
Figure 1.2 Activity of serine protease by cleaving FX to forms FXa. 
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During amplification, FXIa activate FIXa which form a complex with FVIIIa. 
This reaction occurs on vascular phospholipid surface of vessel in the presence of Ca. 
Formation of tenase complex (FVIIIa-FIXa) thus activates sufficient FXa. Activated 
FXa finally form complex with FVa and generate FVa-FXa prothrombin complex. 
Ultimately, enable formation of sufficient fibrin clot after outburst production of 
thrombin (Hoffbrand et al., 2011; Chu, 2011; Dahlbäck et al., 2005). 
 
Briefly, the subsequent activation is played by different form of multimolecular 
complexes. Specifically, tenase complex (FVIIa- FIXa) and prothrombinase complex 
(FVa- FXa) act as procoagulant complexes which prepared by activated platelet. TF, 
FVa, FVIIIa known as cofactor, enzymes such as FVIIa, FIXa, FXa and substrate of 
serine protease (zymogen) are FIX, FX and prothrombin. Formation of complexes is 
induced by product formed by previous reaction of enzyme (Hoffbrand et al., 2011; 
Chu, 2011; Mcintosh, 2005). 
 
In a typical pathway of coagulation measurement, prekallikrein (PK) and high 
molecular weight kininogen (HMWK) are believed to activate FXI, yet in latest finding 
of person with hereditary deficiency of these contact factors, shown the scarcity of 
abnormal bleeding. Due to that, it is been suggest that, these pathways are not involved 
in in vivo physiological of blood coagulation system (Hoffbrand et al., 2011; Bjarne, 
1984). 
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Figure 2.3 Blood coagulation cascade.  Red represents intrinsic, blue is extrinsic 
and green is common pathway (Hoffbrand et al., 2011). 
 
2.2.1 Feedback inhibition of the procoagulant response 
 
Inhibition of procoagulant response is initiated by tissue factor pathway 
inhibitors (TFPI). TFPI are exists on cells surface, plasma, as well as spot of injury due 
to local platelet activation. TFPI will inactivate TF-FVIIa complex by generation of 
quaternary inhibited complex (Peterson et al., 1995).  
 
Other inhibitors that play a pivotal role in inhibition of procoagulant response 
are anti-thrombin (AT) and protein C. AT produce inactive complexes with FIX, FX, 
FXI and impaired thrombin formation. Whereby, activated protein C (APC) together 
with it cofactor, protein S (PS) will rapidly inactivates the procoagulant cofactors FVa 
and FVIIIa by specific proteolysis. These reactions are known as negative feedback 
loop (Friedrich et al., 2001). 
10 
 
PC becomes activated by complex formation of thrombin with thrombomodulin 
(TM), an endothelial cell receptor. Activation of PC also is enhanced by another cellular 
receptor, called endothelial cell protein C receptor (EPCR) (Vanderwouwer et al., 
2004). APC also will reinforce fibrinolysis by inactivate tissue plasminogen activator 
inhibitor (t-PAI) (Figure 2.4). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4  Mechanism involve in inhibition of procoagulant response (Hoffbrand et 
al., 2011). 
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2.2.2 Fibrinolysis 
 
After formation of clot, removal of insoluble fibrin deposition is in urgent needs. 
The system involves plasminogen (PLG) and plasmin, PLG activator and several 
inhibitors of PLG activators and plasmin. PLG activator can be divided into two types 
which are endogenous (tissue or plasma derived) and exogenous (e.g. bacterial or 
venom derived) (Table 2.1) (Hoffbrand et al., 2011). 
 
Fibrinolysis starts after plasminogen converted to plasmin, whereby plasmin 
would degrade at least 50 cleavage site of fibrinogen and transformed it into 
heterogenous mixture or so-called fibrin degradation products (FDPs). Plasmin also has 
a capability in hydrolyzing other substrate such as FV and FVIII (Thorelli et al., 1999). 
Conversion of plasminogen to plasmin is aids by intrinsic (vessel wall) and extrinsic 
(tissues) activation. Specifically, in intrinsic FVIIa and Kallikrein are involved, 
meanwhile in extrinsic, tPA and urokinase-like-A are involved (Figure 2.5) (Dahlbäck 
et al., 2004). 
 
 
 
 
 
 
Figure 2.5  Mechanism of fibrinolysis. Formation of plasmin from plasminogen 
with the aids of PLG activators to formed FDPs (Hoffbrand et al., 2011). 
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In clinical practice, fibrinolytic agent is widely been used such as recombinant 
tPA, incorporated using recombinant DNA technology, streptokinase produce by 
streptococci and urokinase which is taken from human urine. The formation of plasmin 
at the spots of injury restraint the growing thrombus and the ruptured products of 
fibrinolysis also act as inhibitor to thrombin and fibrin polymerization (Dahlbäck et al., 
2004). On the other hand, fibrinolytic system also may be destruct by inhibit the tissue 
plasminogen activator (tPA-i) and α2- Antip  smin  α2-AP) (Hoffbrand et al., 2011). 
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Table 2.1: Key proteins involved in haemostasis network (Hoffbrand et al., 2011) 
Common name Main action 
 
Tissue factor (TF) Cofactor for FVII/ FVIIa 
Prothrombin (FII) Clots FBG, activates PC, FXI, TAFI 
Factor V (FV) Cofactor for FXa 
Factor VII (FII) Activates FIX and FX 
Factor VIII (FVIII) Cofactor for FIXa 
Factor IX (FIX) Activates FX 
Factor X (FX) Activates prothrombin 
Factor XI (FXI) Activates FIX 
Prekallikrein (PK) Anti -  ngiog ni , proﬁbrinolytic 
Factor XIII (FXIII) Cross -  inks ﬁbrin 
Fibrinogen (FGN) Mechanical stabilization of clot 
Von Willebrand Factor (VWF) Cell adhesion and FVIII carrier 
Thrombomodulin (TM) Cofactor in PC/ TAFI activation 
Endothelial 
protein  C  r e c e p t or (EPCR) 
Cofactor in PC activation 
Protein C(PC) Inactivation of FVa  and FVIIIa 
Protein S (PS) Inactivation of FVa and FVIIIa 
Tissue factor 
pathway inhibitor (TFPI) 
Inhibition of coagulation initiation 
 
Antithrombin (AT) Inhibits thrombin, FIX, FX, FXI 
Plasminogen (PLG) Dissolution of clot in wound repair 
Tissue Plasminogen 
Activator (tPA) 
Plasma activator of plasminogen 
 
Prourokinase (UK) Tissue activator of plasminogen 
Tissue Plasminogen Activator 
Inhibitor (t-PAI) 
Inhibition of tPA and uPA 
 
α2- Antiplasmin (α2-AP) Inhibition of plasmin 
Thrombin – activatable  
ﬁbrinolysis inhibitor (TAFI) 
Inhibition of ﬁbrinolysis 
14 
 
2.3 Abnormalities of Coagulation 
 
Haemostasis is vital in providing stable physiology of vascular system. This is 
because hemostasis able to balance formation of clot and thus cleaved it off to produce 
FDPs. Nonetheless, inherited and acquired disorder may disrupt the system and thus 
lead to hypocoagulation (bleeding) or hypercoagulation (thrombosis) of vascular 
system. Coagulation disorder can be passed down through genetics or develop later in 
life. According to James and Thomas (2008), coagulation disorder can be divided into 
two; thrombosis (hypercoagulation) and bleeding (hypocoagulation).  
 
Thrombosis is related to deficiencies of antithrombin III and protein C or S 
cofactors, inhibition of fibrinolysis and related consumptive coagulopathies 
(disseminated intravascular coagulation [DIC]). Thrombosis can be divided into two; 
arterial thrombosis (form in artery) and venous thrombosis (form in vein). Arterial 
thrombosis can cause stroke, cardiac ischaemic and possibly peripheral vascular disease 
(thrombosis in leg arteries). Common cause of arterial thrombosis is artherosclerosis 
which narrowing the artery and thus block the blood flow to vital organ. After acute 
myocardial infarction and stroke, venous thromboembolism normally arose. It is 
represented in two events; acute pulmonary embolism (PE) and deep vein thrombosis 
(VTE) (Previtali et al., 2011). 
 
Meanwhile, bleeding is associated with thrombocytopenia (immune mediatedor 
acquired), toxicosis (warfarin toxicity), inherited disorders (haemophilia A, von 
Wi   br n ’s  is  s ), prim ry fibrinolysis (hyperplasminemia), and disseminated 
intravascular coagulation [DIC]).  
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2.3.1 Anticoagulant of Thrombotic Disorder 
 
 Anticoagulant agent is a drug that has been developed to treat thrombotic 
disorder other than antiplatelet since 20 years ago (Garcia et al., 2009). The use of 
vitamin K antagonist is very effective and had contributed to the remarkable 
achievement for the prevention and treatment of most thrombotic disorder. However, 
still there were considerably limitations of the drug (Table 2.4) (Gresele et al., 2002).  
Due to that, development of novel anticoagulant has been keep progressing (Table 2.2). 
 
Table 2.2: Antithrombotic agent used to treat thrombotic disorder (Gresele et al., 2002) 
 
 Anticoagulant agents 
First generation  Heparin 
 Warfarin 
Second generation  Low-molecular-weight heparins 
 Hirudin 
Novel approaches  Inhibitors of tissue-factor–factor-VIIa 
pathway 
 Selective factor Xa inhibitors 
 Selective thrombin inhibitors 
 Human activated protein C 
 Soluble recombinant thrombomodulin 
 Novel vitamin K antagonist 
 
Warfarin, a coumarin derivative, dicoumarol (bishydroxywarfarin) is isolated 
from spoiled sweet clover by Prof Karl Link in 1939. This compound has proved to 
cause haemorrhagic deaths in cattle. Later, on 1955s warfarin was introduced as an 
anticoagulant agent and been used in clinical practice to treat thrombotic disorder. 
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Dicoumarol able to interfere in cyclic interconversion of vitamin K and 2,3 
epoxide (vitamin K epoxide). The capability of dicoumarol highly contributed to the 
coagulation activity since FII, FVII, FIX and FX are vitamin K dependent protein, 
wh r by vit min K is r quir   to p rform γ- carboxylation to become activated. Hence, 
by inhibiting vitamin K conversion cycle, dicoumarol induced partially decarboxylated 
protein and finally reduced the anticoagulant activity (Hirsh et al., 2003). 
 
 
Figure 2.6 Warfarin actions on coagulation cascade which inhibit production of 
FVIIa, FIXa, FXa and FIIa (shown in green) (Rice et al., 2003). 
 
Another first generation drug invented is heparin. Unfractionated heparin (UFH) 
with molecular weight approximately 15000 Da is a sulphated polysaccharide which 
binds to antithrombin (AT) and coagulation enzyme to inactivate thrombin. By 
inactivating thrombin, fibrin cannot be formed and also inhibit thrombin-induced 
activation of platelet, FV and FVII. Besides that, for inhibition of FXa, only binding to 
AT is required. Thus, in second generation, low molecular weight heparin (LMWH) is 
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invented. Small fragment of heparin with mean molecular weight of 4500 to 5000 Da is 
produced through chemical or enzymatic depolymerization and thus can only fit to bind 
at AT (Hirsh et al., 2001). 
 
Hirudin is an anticoagulant agent that was taken from salivary gland of blood-
sucking leeches (Hirudo medicinalis). It is a natural potent inhibitor of thrombin 
formation and is high quality anticoagulant agent (Markwardt, 2002). However, natural 
source of hirudin is inadequate thus limit it usage in clinical practice. Therefore, 
development of recombinant hirudin such as lepirudin and desirudin through gene 
technology is been developed.   Lepirudin inhibit thrombin formation by blocking the 
active site pocket or catalytic site of thrombin. In contrary to heparin, lepirudin can bind 
to both free and clot-bound thrombin and is a direct thrombin inhibitor (Petros, 2008; 
Greinacher & Lubenow, 2001). 
 
In third generation of anticoagulant agent, all of them are novel and some still 
warrant further study before release. Under each target, there are many agents have been 
progressed (Table 2.3). For inhibition of the tissue-factor–factor-VIIa pathway, 
modulating of inhibitor is aimed to invent the anticoagulant agent. Specifically, 
selective Xa inhibitor can be classified into two, which are direct which bind directly to 
FXa and indirect such as pentasaccharides which need AT to initiate the action (Gresele 
et al., 2002). 
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Whereby, selective thrombin inhibitor can react directly by binding to thrombin 
and thus prevent it interaction with substrate and indirectly, activates AT and cause 
inhibition of thrombin formation. Finally, by increasing soluble thrombomodulin, lead 
to activated protein C and subsequently formation of fibrin polymer (Gresele et al., 
2002). 
 
Table 2.3: Example of novel anticoagulant agent for each target (Garcia et al., 2009; 
Gresele et al., 2002) 
Target Agent 
Inhibition of the tissue-factor–
factor-VIIa pathway 
 Monoclonal antibody against tissue factor  
 Soluble inactive tissue factor  
 Factor VIIai  
 Recombinant nematode anticoagulant 
protein (rNAPc2) Yes  
 Small synthetic inhibitors 
Selective factor Xa inhibitors  Direct natural inhibitors (tick 
anticoagulant peptide, antistasin, lefaxin) 
 Direct synthetic inhibitors (DX9056, 
YM416, SK549) 
 Direct factor Xa inhibitor (Rivaroxaban, 
Apixaban, Betrixaban, YM150, Edoxaban 
(U-176b), Tak-442, Otamixaban) 
 Indirect factor Xa inhibitor (Idraparinux, 
Idrabiotaparinux & Pentasaccharide ) 
Selective thrombin inhibitors  Dermatan sulfate  
 Oral heparin  
 Noncovalent active-site blockers 
Human activated protein C and 
soluble  
 Human recombinant activated protein C 
 Recombinant soluble thrombomodulin 
Vitamin K Antagonist (VKA)  ATI-5923 
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Table 2.4: Anticoagulant agent available in market with its side effect (Jain et al., 2014) 
 
Available drugs Side effects 
Warfarin  Most Common – Tingling sensation, headache, chest, 
abdomen, joint, muscle pain, dizziness, shortness of breath, 
difficulty in breathing and swallowing, weakness, low 
blood pressure and shock. Severe active bleeding during 
pregnancy; documented hypersensitivity - fever, rash and 
hair loss. 
 Gastrointestinal - Nausea, vomiting, diarrhea and 
abdominal pain. 
 Central Nervous System - Fatigue, tiredness, uneasiness, 
weakness, headache, dizziness, loss of consciousness, 
fainting, coma and taste perversion 
Coumarins  Coumarins is a vascular purpura that causes skin necrosis. 
 This is associated with protein C deficiency and 
Malignancy. 
 Coumarins cross the placenta and cause spontaneous 
abortion and specific embryo abnormalities if administered 
in the first trimester of pregnancy. 
Heparin  Major bleeding. Heparin-induced thrombocytopenia (HIT), 
Paradoxical Thrombosis. 
Fondaparinux  Most Common- Mild bleeding, reduced platelet levels 
 (Thrombocytopenia), irritation, rash or itching at the 
injection site. 
 Blood- Bleeding, anemia, blood clot formation, 
postoperative bleeding and bruising. 
 Central Nervous system- Sleeplessness, dizziness and 
confusion. 
 Miscellaneous- Low blood pressure (hypotension), low 
potassium in blood, increase in liver enzymes (elevations of 
hepatic enzymes) and no excess of cardiovascular events. 
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Dalteparin  Skin- Hair loss, skin necrosis. 
 Genitourinary- Blood in urine.(Haematuria) 
 Blood- Any bleeding event, blood clot in the spine. 
 Hypersensitivity- Allergic reactions, including itching, rash, 
fever, injection-site reaction, hypersensitivity reactions. 
 Local- Injection-site blood clot, wound hematoma, 
injection-site pain  
Lepirudin  Heart- Heart failure. 
 Skin- Bleeding in injection site, wounds and allergic skin 
reactions. 
 Eye and ENT- Nosebleed. (Epistasis) 
 Gastrointestinal- Gastrointestinal and rectal bleeding. 
 Genitourinary- Abnormal kidney function, blood in urine 
and vaginal bleeding. 
 Blood- Anemia and sepsis, Liver- Abnormal liver function. 
 Respiratory- Pneumonia. 
 Miscellaneous- Fever and infection  
Urokinase  Most Common- Severe bleeding. (Haemorrhage) 
 Heart - Heart attack, pulmonary embolism. 
 Blood- Decreased red blood cells and platelets. 
 Miscellaneous- Excess sweating. 
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2.4 Mikania cordata 
 
2.4.1 Taxonomical classification and Nomenclature  
 
Mikania cordata (Bum. F.) B.L Robinson belongs to family of Asteraceae. 
Generally, through the classification, M. cordata can be describes as vascular, seed, 
flowering, dicot and hempvine plant (Figure 2.7).  
 
Kingdom : Plantae 
      Subkingdom : Tracheobionta 
             Superdivision : Spermatophyta 
                   Division : Magnoliophyta 
                        Class : Magnolipsida 
                              Subclass : Asteridae 
                                    Order : Asterales 
                                          Family                          : Asteraceae 
                                                Genus : Mikania 
                                                       Species : Mikania cordata 
 
Figure 2.7 Taxonomical classification of M. cordata (Adapted from NRCS, United 
States Department of Agriculture). 
 
Scientifically, it is also called as Eupatorium cordatum Burm. F. It is commonly 
known as heartleaf hempvine due to its shape and trailing characteristic. In Malaysia, it 
is known as ulam tikus, akar lupang and selaput tunggul. Belows is the common or 
vernacular name of M. cordata. It is called differently according to particular language 
and region (Table 2.4).  
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Table 2.5: Nomenclature of M. cordata (Al Nayeem et al., 2011; Zerin et al., 2012; 
Biswas et al., 2011; Ahmed et al., 2008) 
 
Country/Language Common / Vernacular Name 
English Mile-a-minute 
Bangladesh Assamlata, Germanlata Taralata Dubainna 
lota and Refugee 
Philippine (Tagalog) Bikas 
China Mi Gan Cao 
Indonesia Sembung rambat 
Thailand Khikaiyanna 
Malaysia (Malay language) Ulam tikus, Akar lupang and Selaput 
tunggul 
 
2.4.2 Distribution and Botanical Description  
 
 M. cordata is a creeping woody perennial which grow in tropical regions of 
Africa, Asia (Malaysia, Bangladesh, India, Philippine, China, Indonesia, Thailand), 
Brazil and South America (Argentina, Paraguay and Uruguay) (Chowdhury et al., 2011; 
Aguinaldo et al., 2003). 
 
 Physically, M. cordata is a plant with smooth vines and consist of 4 to 10 cm 
length of green leaves. The shape of leaves is deltoid-ovoid or so-called ovate heart-
shaped. Apparently, it has long –petioled with pointed tip, truncate base and toothed 
margins.  M. cordata also produce many white flowers (Ahmed, 2008) with length 
between 6 to 9 mm, cylindrical in shape which is borne in compound inflorescences 
(Figure 2.8). Typically, M. cordata’s flower bloom during dry season (Al Nayeem et 
al., 2011; Rahman et al., 2008). 
